ENA-001, a New Chemical Entity (NCE) with a novel mechanism of action as an agnostic respiratory stimulant, has previously been granted Rare Pediatric Disease designation for the Treatment of AoP by the FDA, with eligibility for a priority review voucher (PRV). The compound is also being developed by Enalare for the treatment of post-operative respiratory depression and community drug overdose.

The Funding Will Accelerate Development of an Intramuscular Formulation of ENA-001, a Novel Agnostic Respiratory Stimulant, for the Potential Treatment of Community Drug Overdose and as a Medical Countermeasure for Mass Casualty Events. The Funding Supports Development of an Intramuscular ENA-001 From Pre-Clinical Toxicology Through Filing for Approval in the United States

Sitero has expanded its leadership team to support the expected rapid growth of its business.

The Collaborative Genomics Standards Workshop hosted by GA4GH will be facilitated by Bron Kisler (Nurocor) and Lindsay Smith (GA4GH)

Together the two companies will expand their reach and capabilities to better serve the Pharma and Biotech Industries

Sewon E&C completes FDA registration of ultra-thin flexible OLED phototherapy patch

Neovii and Fosun Pharma Enter into an Exclusive Agreement for Development and Commercialization for Grafalon in China

Development of a sublingual COVID-19 subunit vaccine: the potential for a better protective efficacy and improved thermal stability during distribution and storage as compared to conventional COVID-19 vaccines

Seattle-based primary cell biology CRO ReachBio and Swiss biotech abc biopply announced today a partnership to jointly co-market their preclinical test models. The two companies plan to support their clients with an even more predictive assay portfolio to further increase the efficiency of their drug discovery and development process.

In collaboration with Swiss precision manufacturer CSEM, 3Brain AG has announced an exciting 3D microchip for their brain-on-chip portfolio. This first-in-class cell-electronic interface technology will allow scientists to study the complexity of 3D cellular networks at unrivalled scale and precision - and to gain novel mechanistic insights into the inner workings of the most complex structure in the universe: the human brain.

After months of experimentation in partnership with some world-class schools of medicine and top-tier diagnostic providers, the much-anticipated T-Cell Test from Hyris, based on innovative qPCR technology, is finally available for the European market with a CE-IVD mark. The new Test will change the way laboratories and diagnostic providers track and monitor T-cell patients' immunity to SARS-CoV-2, leveraging the unique characteristics of the Hyris System™.

Collaboration provides an industry-leading offering for Life Sciences Companies

Integrated QC dashboard and unlimited validation cycles for interim and final datasets creates industry's most user-friendly validator

World-first as adaptive chemical space is launched as a service

Latest milestone brings the Selux Next-Generation Phenotyping (NGP) platform one step closer to impacting patient care with same-shift Antibiotic Susceptibility Testing (AST).

CaaMTech will help carry on Dr. Alexander Shulgin's legacy by developing ASRI's novel compounds

Funding from the NIH's National Institute on Drug Abuse (NIDA) will Support Further Development of ENA001, an Agnostic Respiratory Stimulant

Patients from Montgomery, Berks, and Chester Counties will now have access to clinical trials managed by Labcorp

Australian biotech Skin2Neuron Pty Ltd (S2N) has achieved what no one has to date - reversal of a dementia-like syndrome in a natural animal form of Alzheimer's disease.

This is the new fantasy creature from the Phantasticals campaign that Ferrer has relaunched, coinciding with Global Amyotrophic Lateral Sclerosis (ALS) Awareness Day, on June 21. The aim is to raise public awareness of this rare, neurodegenerative, progressive disease that affects the motor neurons in the brain. Ferrer is leading the ADORE Phase III clinical trial to evaluate the safety and efficacy of the investigational drug FNP122 in the treatment of ALS.

Globally recognized leader in international standards development joins the leader in digitalized clinical development.

A scientific paper recently published in Nature Biotechnology reveals new research regarding how we track and monitor T-cell patients' immunity to SARS-CoV-2, leveraging the unique characteristics of Hyris System™. The study results from a joint effort of an international research team from the Icahn School of Medicine at Mount Sinai, Singapore Duke-NUS Medical School, laboratory diagnostic service providers Synlab, and Hyris.